Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma

Archive ouverte

van de Wyngaert, Zoé | Coppo, Paul | Cervera, Pascale | Fabiani, Bettina | Lemonnier, Marie‐paule | Corre, Elise | Marjanovic, Zora | Aoudjhane, Malek | Mohty, Mohamad | Duléry, Rémy

Edité par CCSD ; Wiley -

International audience. ObjectivesRelapsed/refractory peripheral T‐cell lymphomas (PTCL) have a poor prognosis. We aimed at assessing efficacy of ifosfamide, carboplatin, etoposide (ICE) regimen, a known therapeutic option, to which we added brentuximab‐vedotin (BV).MethodsIn this study, we retrospectively analyzed patients with PTCL treated with BV‐ICE in our center between July 2014 and March 2018.ResultsFourteen patients received BV‐ICE. Median age was 62 years (range, 31‐73). Main histological subtypes were PTCL‐not otherwise specified (29%), angioimmunoblastic T‐cell lymphoma (21%), follicular‐T helper (21%), or anaplastic large‐cell (15%) lymphomas, all were CD30 positive. Overall response was seen in four (29%) patients, and complete response (CR) in two (14%). Most frequent adverse events were infections, and cytopenia. 2‐year progression‐free and overall survival were 14% and 17.5%, respectively.ConclusionPatients with relapsed/refractory PTCL treated with BV‐ICE can achieve CR, but few had a sustained response. This association should preferably be used as a bridge to stem cell transplant or be followed by maintenance therapy.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion